Biomarker Discovery: A Key to Overcoming Rare Diseases

This NCT00344331 study, led by the National Institute of Child Health and Human Development (NICHD) at the National Institutes of Health, aims to track the progression of Niemann-Pick disease type C (NPC), a life-threatening rare neurodegenerative disorder. Objective and reliable biochemical biomarkers are essential to verify whether a drug is functioning properly in the body. This research focuses on patients with this genetic disorder, caused by impaired lysosomal function, to establish indicators that can quantitatively measure the degree of disease progression. This is crucial as it provides critical baseline data that can evaluate the efficacy of new drug candidates and increase the likelihood of clinical success.

Securing Disease Progression Data Through Comprehensive and Precise Testing

The research team is closely defining the rate of neurological degeneration by collecting cerebrospinal fluid (CSF) from patients, performing magnetic resonance imaging (MRI), and measuring proteins and oxysterols in the CSF. In particular, plasma oxysterol markers, such as 24S-hydroxycholesterol, are being actively considered as key biomarkers that show a correlation with the stage of disease progression. The collection of this precise data will enable real-time tracking of a drug's therapeutic response during the new drug development process, enabling precision medicine. This is expected to be a powerful tool that significantly reduces uncertainty in clinical trial design for single-therapy studies.

Clinical Relevance to 2024 FDA-Approved Drugs

This natural history study may have indirectly contributed to or will critically contribute to the accumulation of real-world data (RWD) that led to the historic FDA approval of Zevra Therapeutics' (ZVRA) Miplyffa (arimoclomol) and IntraBio's Aqneursa (levacetylleucine) in September 2024. Miplyffa, which induces Hsp70 response to improve lysosomal function, was approved as a combination therapy with miglustat, the existing standard treatment. The long-term cohort data collected by NICHD, used as a comparative control group to verify this therapeutic efficacy, has become a key reference to indirectly demonstrate the efficacy of the new drug.

Strategic Value of Large Patient Cohort and Long-Term Data

Niemann-Pick disease type C is an ultra-rare disease with a very low prevalence worldwide, making it extremely difficult to recruit patients and secure long-term data. NICHD's long-term observational study significantly expands the expected number of registered participants to 900, establishing neurological degradation patterns across all age groups, from infants to adults. This serves as a public infrastructure that reduces risk for companies developing treatments for rare diseases, and will be a solid stepping stone to help next-generation gene therapies or targeted lysosome-activating new drugs rapidly enter Phase 1/2 clinical trials.